Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene cause late-onset, autosomal dominant familial Parkinson's disease (PD) and also contribute to idiopathic PD. LRRK2 mutations represent the most common cause of PD with clinical and neurochemical features that are largely indistinguishable from idiopathic disease. Currently, transgenic mice expressing wild-type or disease-causing mutants of LRRK2 have failed to produce overt neurodegeneration, although abnormalities in nigrostriatal dopaminergic neurotransmission have been observed. Here, we describe the development and characterization of transgenic mice expressing human LRRK2 bearing the familial PD mutations, R1441C and G2019S. Our study demonstrates that expression of G2019S mutant LRRK2 induces the degeneration of nigrostriatal pathway dopaminergic neurons in an age-dependent manner. In addition, we observe autophagic and mitochondrial abnormalities in the brains of aged G2019S LRRK2 mice and markedly reduced neurite complexity of cultured dopaminergic neurons. These new LRRK2 transgenic mice will provide important tools for understanding the mechanism(s) through which familial mutations precipitate neuronal degeneration and PD.

[1]  Richard Wade-Martins,et al.  LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. , 2009, Human molecular genetics.

[2]  David W. Miller,et al.  Kinase activity is required for the toxic effects of mutant LRRK2/dardarin , 2006, Neurobiology of Disease.

[3]  E. Tolosa,et al.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.

[4]  C. Olanow,et al.  Leucine‐rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson’s disease R1441C/G mutants , 2007, Journal of neurochemistry.

[5]  M. Geyer The family of sensorimotor gating disorders: Comorbidities or diagnostic overlaps? , 2006, Neurotoxicity Research.

[6]  T. Gasser Mendelian forms of Parkinson's disease. , 2009, Biochimica et biophysica acta.

[7]  R. Burke,et al.  Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease , 2009, Nature Neuroscience.

[8]  T. Dawson,et al.  Value of genetic models in understanding the cause and mechanisms of Parkinson’s disease , 2008, Current neurology and neuroscience reports.

[9]  T. Dawson,et al.  Parkin mediates the degradation‐independent ubiquitination of Hsp70 , 2008, Journal of neurochemistry.

[10]  T. Katada,et al.  GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. , 2007, Biochemistry.

[11]  Sara Cipolat,et al.  OPA1 Controls Apoptotic Cristae Remodeling Independently from Mitochondrial Fusion , 2006, Cell.

[12]  M. Cookson,et al.  LRRK2 Modulates Vulnerability to Mitochondrial Dysfunction in Caenorhabditis elegans , 2009, The Journal of Neuroscience.

[13]  Irene Litvan,et al.  Lrrk2 and Lewy body disease , 2006, Annals of neurology.

[14]  H. Guo,et al.  Improved neuronal transgene expression from an AAV‐2 vector with a hybrid CMV enhancer/PDGF‐β promoter , 2005, The journal of gene medicine.

[15]  H. Cai,et al.  The Chaperone Activity of Heat Shock Protein 90 Is Critical for Maintaining the Stability of Leucine-Rich Repeat Kinase 2 , 2008, The Journal of Neuroscience.

[16]  L. Petrucelli,et al.  Inhibitors of Leucine Rich Repeat Kinase 2 (LRRK2) Protect Against LRRK2-Models of Parkinson’s Disease , 2010, Nature Medicine.

[17]  O. Sydow,et al.  LRRK2 expression linked to dopamine‐innervated areas , 2006, Annals of neurology.

[18]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[19]  H. Cai,et al.  Leucine-Rich Repeat Kinase 2 Regulates the Progression of Neuropathology Induced by Parkinson's-Disease-Related Mutant α-synuclein , 2009, Neuron.

[20]  K. Lim,et al.  Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. , 2007, Human molecular genetics.

[21]  M. Cookson,et al.  Leucine-rich repeat kinase 2 mutations and Parkinson’s disease: three questions , 2009, ASN neuro.

[22]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[23]  P. Aebischer,et al.  A Rat Model of Progressive Nigral Neurodegeneration Induced by the Parkinson's Disease-Associated G2019S Mutation in LRRK2 , 2011, The Journal of Neuroscience.

[24]  Naoki Hisamoto,et al.  LRK-1, a C. elegans PARK8-Related Kinase, Regulates Axonal-Dendritic Polarity of SV Proteins , 2007, Current Biology.

[25]  C. Ross,et al.  Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M V Ovanesov,et al.  Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia , 2008, Molecular Psychiatry.

[27]  C. Ross,et al.  A Drosophila model for LRRK2-linked parkinsonism , 2008, Proceedings of the National Academy of Sciences.

[28]  R. J. Kelleher,et al.  Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice , 2010, Proceedings of the National Academy of Sciences.

[29]  C. Ross,et al.  Kinase activity of mutant LRRK2 mediates neuronal toxicity , 2006, Nature Neuroscience.

[30]  Christine Klein,et al.  LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. , 2006, The New England journal of medicine.

[31]  D. Borchelt,et al.  Amyloid Pathology Is Associated with Progressive Monoaminergic Neurodegeneration in a Transgenic Mouse Model of Alzheimer's Disease , 2008, The Journal of Neuroscience.

[32]  K. Lim,et al.  Parkin Protects against LRRK2 G2019S Mutant-Induced Dopaminergic Neurodegeneration in Drosophila , 2009, The Journal of Neuroscience.

[33]  J. Trojanowski,et al.  Biochemical and pathological characterization of Lrrk2 , 2006, Annals of neurology.

[34]  M. Cookson,et al.  The R1441C mutation of LRRK2 disrupts GTP hydrolysis. , 2007, Biochemical and biophysical research communications.

[35]  Andrew B West,et al.  Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Kazuko Hasegawa,et al.  An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family , 2005, Annals of neurology.

[37]  T. Dawson,et al.  Conditional transgenic mice expressing C-terminally truncated human α-synuclein (αSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons , 2009, Molecular Neurodegeneration.

[38]  I. Marín The Parkinson disease gene LRRK2: evolutionary and structural insights. , 2006, Molecular biology and evolution.

[39]  P. Emson,et al.  Localization of Parkinson’s disease-associated LRRK2 in normal and pathological human brain , 2007, Brain Research.

[40]  P. Emson,et al.  Localization of LRRK2 to membranous and vesicular structures in mammalian brain , 2006, Annals of neurology.

[41]  A. Pisani,et al.  R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice , 2009, Proceedings of the National Academy of Sciences.

[42]  J. Buxbaum,et al.  Enhanced Striatal Dopamine Transmission and Motor Performance with LRRK2 Overexpression in Mice Is Eliminated by Familial Parkinson's Disease Mutation G2019S , 2010, The Journal of Neuroscience.

[43]  R. Nichols,et al.  LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. , 2007, The Biochemical journal.

[44]  Zilong Qiu,et al.  A Calcium-Dependent Switch in a CREST-BRG1 Complex Regulates Activity-Dependent Gene Expression , 2008, Neuron.

[45]  M. Beal,et al.  Unexpected Lack of Hypersensitivity in LRRK2 Knock-Out Mice to MPTP (1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine) , 2009, The Journal of Neuroscience.

[46]  J. McCaffery,et al.  Localization of GTPases by indirect immunofluorescence and immunoelectron microscopy. , 1995, Methods in enzymology.

[47]  C. Chu,et al.  Role of autophagy in G2019S‐LRRK2‐associated neurite shortening in differentiated SH‐SY5Y cells , 2008, Journal of neurochemistry.

[48]  H. Cai,et al.  Phosphorylation of Ezrin/Radixin/Moesin Proteins by LRRK2 Promotes the Rearrangement of Actin Cytoskeleton in Neuronal Morphogenesis , 2009, The Journal of Neuroscience.

[49]  S. Wang,et al.  CMV enhancer/human PDGF-beta promoter for neuron-specific transgene expression. , 2004, Gene therapy.

[50]  P. Pollak,et al.  LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. , 2006, The New England journal of medicine.

[51]  Nicholas W Wood,et al.  A common LRRK2 mutation in idiopathic Parkinson's disease , 2005, The Lancet.

[52]  A. Gitler,et al.  GTPase Activity Plays a Key Role in the Pathobiology of LRRK2 , 2010, PLoS genetics.

[53]  P. Bickford,et al.  Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: Implications for Parkinson’s disease , 2008, Neuroscience.

[54]  L. Mucke,et al.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.

[55]  Mark J. West,et al.  New stereological methods for counting neurons , 1993, Neurobiology of Aging.

[56]  Z. Wszolek,et al.  PARK8 LRRK2 parkinsonism , 2006, Current neurology and neuroscience reports.

[57]  David I. Bass,et al.  Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice , 2010, Neurobiology of Disease.

[58]  Tatiana Foroud,et al.  Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease , 2005, The Lancet.

[59]  A. Abeliovich,et al.  The Familial Parkinsonism Gene LRRK2 Regulates Neurite Process Morphology , 2006, Neuron.

[60]  Shu Wang,et al.  CMV enhancer/human PDGF-β promoter for neuron-specific transgene expression , 2004 .

[61]  D. Moore The biology and pathobiology of LRRK2: implications for Parkinson's disease. , 2008, Parkinsonism & related disorders.

[62]  R. Bodmer,et al.  Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons , 2008, Molecular Neurodegeneration.